Undisclosed CSF1R inhibitor / Myrobalan Therap - LARVOL DELTA

Myrobalan Therapeutics Receives a Grant from the ALS Association to Advance its CSF1R Inhibitor Program (Businesswire) - "Myrobalan Therapeutics...is honored to announce a $400,000 grant from the ALS Association to support the advancement of its colony-stimulating factor-1 receptor (CSF1R) inhibitor for the treatment of amyotrophic lateral sclerosis (ALS). The grant has been made through the Association’s Lawrence and Isabel Barnett Drug Development Program, supplementing the previously announced $24 million in Series A funding in January 2024....The company is currently conducting IND-enabling studies and developing a clinical biomarker strategy in preparation for its first-in-human clinical trial expected to begin in 2025."

Financing • New trial • Amyotrophic Lateral Sclerosis • CNS Disorders